Valuation: Prenetics Global Limited

Market Cap 332M 292M 269M 252M 472M 31.36B 480M 3.23B 1.25B 15.46B 1.25B 1.22B 53.72B P/E 2026 *
-7.53x
P/E 2027 * -32.9x
Enterprise Value 332M 292M 269M 252M 472M 31.36B 480M 3.23B 1.25B 15.46B 1.25B 1.22B 53.72B EV / Sales 2026 *
1.64x
EV / Sales 2027 * 1.04x
Free-Float
85.39%
Yield 2026 *
-
Yield 2027 * -
1 day+0.15%
1 week-3.66%
Current month-6.40%
1 month+17.77%
3 months-8.40%
6 months+16.79%
Current year+25.40%
1 week 19.21
Extreme 19.21
20.5
1 month 16.88
Extreme 16.88
22.22
Current year 14
Extreme 14
23.63
1 year 7.18
Extreme 7.175
23.63
3 years 2.85
Extreme 2.85
23.63
5 years 2.85
Extreme 2.85
131.25
10 years 2.85
Extreme 2.85
131.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 52 31/12/2013
Chief Executive Officer 47 31/12/2013
Director of Finance/CFO 41 31/12/2017
Director TitleAgeSince
Chairman 47 31/12/2013
Director/Board Member 38 -
Director/Board Member 60 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
06-14Fiscal year

Director

31,746 0.2082%
06-14Fiscal year

Director

15,625 0.1025%
06-03Other

Director

24,004 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%-3.66%+153.53%+45.83% 332M
+3.04%+5.46%-32.14%-13.71% 162B
+0.49%+1.49%-6.34%-7.96% 103B
+0.87%+5.56%-1.84%+52.90% 55.83B
-2.09%-6.13%+51.65%+53.01% 54.05B
+2.44%+5.14%-11.42%-40.99% 41.71B
+4.77%+5.09% - - 31.94B
-1.58%-5.27%-18.93%-45.84% 26.49B
+1.81%+5.67%+56.80%-5.57% 24.48B
+1.66%+3.94%-12.39%-0.10% 20.52B
Average +1.16%+1.16%+19.88%+4.17% 52.08B
Weighted average by Cap. +1.48%+2.26%-6.08%-0.56%

Financials

2026 *2027 *
Net sales 203M 178M 164M 154M 288M 19.15B 293M 1.97B 763M 9.44B 762M 745M 32.8B 319M 280M 258M 242M 453M 30.13B 461M 3.1B 1.2B 14.85B 1.2B 1.17B 51.61B
Net income -48.71M -42.79M -39.42M -36.86M -69.13M -4.6B -70.4M -473M -183M -2.27B -183M -179M -7.87B -9.62M -8.45M -7.79M -7.28M -13.66M -908M -13.91M -93.43M -36.19M -448M -36.13M -35.34M -1.56B
Net Debt - -
Logo Prenetics Global Limited
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Employees
98
Date Price Change Volume
25/06/26 US$19.75 +0.15% 55,895
24/06/26 US$19.72 -1.00% 111,861
23/06/26 US$19.92 -0.20% 91,740
22/06/26 US$19.96 -2.63% 176,187
18/06/26 US$20.50 +3.25% 140,303
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
19.75USD
Average target price
31.00USD
Spread / Average Target
+56.96%

Quarterly revenue - Rate of surprise